Chad Landmon is co-chair of Axinn, Veltrop & Harkrider LLP’s intellectual property practice and chair of the firm’s FDA Practice Group. Mr. Landmon focuses his practice on patent litigation and counseling and food and drug law, with an emphasis on pharmaceuticals, biologics and human tissue products. He maintains a particular focus on Paragraph IV patent litigation, having litigated dozens of cases for numerous pharmaceutical companies involving a wide variety of products, including on many blockbuster products. By coupling his patent litigation experience with his FDA expertise, Chad enables pharmaceutical clients to develop and execute on patent and FDA strategies to bring products to market in the most efficient and profitable manner.
360
Over the past decade, practitioners, policy makers and commentators have increasingly debated the issues involved when the antitrust laws intersect with patent rights. Both the antitrust and patent laws are designed to promote competition and, as a result, societal wellbeing. However, (...)
251
Over the past decade, practitioners, policy makers and commentators have increasingly debated the issues involved when the antitrust laws intersect with patent rights. Both the antitrust and patent laws are designed to promote competition and, as a result, societal wellbeing. However, the (...)
181
On April 4, 2001, the Federal Trade Commission (“FTC”) took the unusual step of voting to file a complaint in the United States District Court for the District of Columbia against The Hearst Trust, its subsidiary The Hearst Corporation, and First DataBank, a wholly owned subsidiary of (...)
